Safety of an immunomodulator Mycobacterium w in COVID-19
Main Authors: | Inderpaul Singh Sehgal, Ashish Bhalla, Goverdhan Dutt Puri, Laxmi Narayana Yaddanapudi, Mini Singh, Pankaj Malhotra, Sahajal Dhooria, Vikas Suri, Ritesh Agarwal |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2020-01-01
|
Series: | Lung India |
Online Access: | http://www.lungindia.com/article.asp?issn=0970-2113;year=2020;volume=37;issue=3;spage=279;epage=281;aulast=Sehgal |
Similar Items
-
A randomised trial of Mycobacterium w in critically ill patients with COVID-19: ARMY-1
by: Inderpaul Singh Sehgal, et al.
Published: (2021-04-01) -
Ignotum per ignotius
by: Milind Baldi, et al.
Published: (2019-01-01) -
Clinical significance and epidemiological evolution of epitrochlear lymphadenopathy in pre- and post-highly active antiretroviral therapy era: A systematic review of the literature
by: Valliappan Muthu, et al.
Published: (2018-01-01) -
Primary cavitary sarcoidosis: A case report, systematic review, and proposal of new diagnostic criteria
by: Ajay Handa, et al.
Published: (2018-01-01) -
“Pearl” in the lung: Hydatid membrane
by: Milind Baldi, et al.
Published: (2019-01-01)